TRENTON, N.J. (AP) - The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis. The FDA late Monday ...
On Wednesday, GSK Plc (NYSE:GSK) announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all its asthma and chronic obstructive pulmonary disease (COPD) ...
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending ...
The U.S. Food and Drug Administration has approved GlaxoSmithKline’s Incruse Ellipta (umeclidinium) as a treatment for patients with chronic obsessive pulmonary disease, according to a Medscape report ...
* Darrell baker, SVP & head, GSK Global Respiratory Franchise says - This is in line with our goal to develop a range of respiratory medicines that allow physicians to make treatment choices based on ...
Adherium, a New Zealand-based maker of connected respiratory medical devices, has received the US Food and Drug Administration's 510(k) clearance for connecting its digital monitoring platform with ...
Verywell Health on MSN
Don’t Combine These COPD Medicines
Beta-2 adrenergic agonists (also known as beta-agonists) are a mainstay treatment for COPD. There are short-acting versions used as rescue inhalers and long-acting versions that are used to control ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback